Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 1:41 AM
Ignite Modification Date: 2025-12-25 @ 1:41 AM
NCT ID: NCT00257894
Eligibility Criteria: Inclusion Criteria: * Smoke at least 10 cigarettes per day for at least 6 months and considering quitting smoking in the next 6 months- Exclusion Criteria: * Planning to attempt smoking cessation within the next 4 months * Weight less than 110 lbs. or above 220 lbs. * Use of tobacco products other than cigarettes in the previous month. * History of: Kidney disease, uncontrolled conditions (e.g., cardiac disease, pulmonary disease, diabetes, hypertension) Neurological disease (including stroke, mini-stroke, brain injury, Alzheimers Disease, encephalitis, meningitis, seizure disorder),Phenylketonuria Schizophrenia, Schizoaffective Disorder, Paranoid Disorder, or Schizotypal Disorder. * Current alcohol and/or drug use disorder as indicated by a screening questionnaire, past treatment for alcohol or substance use problems unless in remission(clean and sober for past year or more) or intention to seek treatment in the next 6 months for alcohol or substance use problems. * For women: Pregnancy, nursing, not using a reliable form of birth control. * Allergy to baclofen, Lioresal, or Kemstro. * Taking the following medications: antidepressants(excluding selective serotonin reuptake inhibitors), bupropion, phenothiazines, antihistamines, sedative/hypnotics, benzodiazepines, alpha blockers, beta blockers. * Lives with someone enrolled in the study.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 65 Years
Study: NCT00257894
Study Brief:
Protocol Section: NCT00257894